Terms: = Pancreatic cancer AND CgA AND Staging
9 results:
1. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation.
Noor M; Huber AR; Cates JMM; Gonzalez RS
Histopathology; 2021 Sep; 79(3):416-426. PubMed ID: 33754384
[TBL] [Abstract] [Full Text] [Related]
2. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
[TBL] [Abstract] [Full Text] [Related]
4. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract] [Full Text] [Related]
5. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors.
Denecke T; Baur AD; Ihm C; Steffen IG; Tischer E; Arsenic R; Pascher A; Wiedenmann B; Pavel M
Eur J Radiol; 2013 Oct; 82(10):e550-5. PubMed ID: 23891296
[TBL] [Abstract] [Full Text] [Related]
7. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
Lindholm DP; Oberg K
Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
[TBL] [Abstract] [Full Text] [Related]
8. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
Massironi S; Conte D; Sciola V; Spampatti MP; Ciafardini C; Valenti L; Rossi RE; Peracchi M
Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
[TBL] [Abstract] [Full Text] [Related]
9. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours.
Nehar D; Lombard-Bohas C; Olivieri S; Claustrat B; Chayvialle JA; Penes MC; Sassolas G; Borson-Chazot F
Clin Endocrinol (Oxf); 2004 May; 60(5):644-52. PubMed ID: 15104570
[TBL] [Abstract] [Full Text] [Related]
